United Therapeutics Unveils Net Zero Energy Distribution Center
14 Junho 2023 - 7:00AM
Business Wire
First-of-its-kind distribution and warehouse center introduces a
holistic approach to operations and energy management
Facility poised to support United Therapeutics’ near-term growth
objective of doubling its revenue run rate to $4 billion annually
by the middle of this decade
Opening event featured United Therapeutics’ Chairperson and CEO
Dr. Martine Rothblatt and North Carolina Secretary of Commerce
Machelle Baker Sanders
United Therapeutics Corporation (Nasdaq: UTHR), a public
benefit corporation, yesterday unveiled its new net zero energy
distribution center located on the company’s co-headquarters campus
in Research Triangle Park, North Carolina.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230614359824/en/
United Therapeutics Chairperson and CEO
Martine Rothblatt delivers opening remarks at the company's Phase
Five dedication ceremony. (Photo: Business Wire)
United Therapeutics Chairperson and CEO Dr. Martine
Rothblatt welcomed North Carolina officials, members of the
North Carolina General Assembly, and business leaders to a “cord
cutting” ceremony to showcase the new distribution center. Dubbed
“Phase Five,” the new building is the second site net zero building
on the company’s Research Triangle Park Campus, and the fifth
overall in its sustainable portfolio. The 55,000-square-foot
facility features a new warehouse designed to meet current good
manufacturing practices (cGMP) for pharmaceutical products
and boasts a microgrid-based electrical system designed to run
without any fossil fuels via battery backup using two Tesla
Megapacks. Among other things, the facility will be used to store
and distribute the company’s newest drug-device combination
product, Tyvaso DPI®, which was launched last year. To store
pharmaceutical products, a cGMP facility must meet exacting
standards for 24/7 temperature control, making a net zero design an
especially challenging goal.
“As far as we are aware, this is the first cGMP warehouse
designed to meet site net zero energy standards. Achieving this
goal required extensive collaboration with the city and county of
Durham and with our local electric utility, Duke Energy,” said Dr.
Rothblatt. “We are extremely grateful to all our employees and
collaborators who worked tirelessly to design and construct this
facility, which is one of the keys to supporting our near-term
revenue growth expectations.”
“We’re proud to serve as home to a company known not just for
its life-changing therapies, but also for its environmental
stewardship—and this innovative distribution center exemplifies how
North Carolina corporations can lead the way in sustainability,”
said North Carolina Commerce Secretary Machelle Baker
Sanders. “We greatly appreciate United Therapeutics’
partnership and its continued investment in North Carolina’s life
sciences industry.”
Key details for the zero net energy distribution center
include:
- A geothermal system consisting of 40 vertical bores, each six
inches in diameter and 500 feet deep. The system uses core earth
temperatures to regulate building systems and environmental
conditions and is designed to add future capacity if needed.
- A microgrid with battery backup using Tesla Megapacks that
provide 6.2 MWh of battery capacity to support the building through
an outage of two-plus days without utility power, using zero fossil
fuels.
- A roof-mounted photovoltaic (PV) system includes 1,200
PV panels with 560 kW peak output and 767 MWh of projected annual
production and net metering with Duke Energy, the local electric
utility. The PV system is connected to the project’s microgrid and
can recharge the Tesla Megapack when the building electrical system
is disconnected from the utility, allowing the facility to operate
for an extended period. This results in a design that does not
include a standby generator.
- Smart building technology, including lighting occupancy sensors
in strategic locations, ENERGY STAR-certified office equipment, and
regenerative charging lift trucks.
Engineering, architectural, and construction firms for the
project include: Hanbury Architects, Affiliated Engineers, Inc.,
DPR Construction, Stranix Associates, Surface 678, PA, and
Cornerstone Commissioning, Inc.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use
our enthusiasm, creativity, and persistence to innovate for the
unmet medical needs of our patients and to benefit our other
stakeholders. We are bold and unconventional. We have fun, we do
good. We are the first publicly-traded biotech or pharmaceutical
company to take the form of a public benefit corporation
(PBC). Our public benefit purpose is to provide a brighter
future for patients through (a) the development of novel
pharmaceutical therapies; and (b) technologies that expand the
availability of transplantable organs.
You can learn more about what it means to be a PBC here:
unither.com/PBC.
Forward-Looking Statements
Statements included in this press release that are not
historical in nature are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, our revenue
growth goals, including our goal of doubling our revenue run rate
by the end of 2025, the net zero energy performance and cGMP
compliance of our new Phase 5 distribution center, our efforts to
innovate for the unmet medical needs of our patients, to benefit
our other stakeholders, and to pursue our public benefit purpose of
developing novel pharmaceutical therapies and technologies that
expand the availability of transplantable organs. These
forward-looking statements are subject to certain risks and
uncertainties, such as those described in our periodic reports
filed with the Securities and Exchange Commission, that could cause
actual results to differ materially from anticipated results.
Consequently, such forward-looking statements are qualified by the
cautionary statements, cautionary language, and risk factors set
forth in our periodic reports and documents filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. We claim the protection of the safe
harbor contained in the Private Securities Litigation Reform Act of
1995 for forward-looking statements. We are providing this
information as of June 14, 2023 and assume no obligation to update
or revise the information contained in this press release whether
as a result of new information, future events or any other
reason.
TYVASO DPI is a registered trademark of United Therapeutics
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230614359824/en/
Dewey Steadman at (202) 919-4097 Email: ir@unither.com
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024